Overview

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
To investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension
Phase:
Phase 2
Details
Lead Sponsor:
Santen Inc.
Treatments:
Latanoprost
Ophthalmic Solutions
Pharmaceutical Solutions